TFFP News and Press, TFF Pharmaceuticals Inc - Ordinary Shares From 11/15/21

TFF Pharmaceuticals (NASDAQ:TFFP): Q3 GAAP EPS of -$0.34 misses by $0.13. Revenue of $0.05M misses by $1.08M. Press Release For further details see: TFF Pharmaceuticals EPS misses by $0.13, misses on revenue

Positive Updates Announced for Inhaled Voriconazole and Tacrolimus Programs; Both Programs Advancing into Phase 2 Testing Continued Progress with Partnered Antiviral Programs for AUG-3387 and Niclosamide Thin Film Freezing Applications Continue to Expand Across Diver...

TFF Pharmaceuticals (NASDAQ:TFFP) announces the completion of dosing in the Phase 1b trial of Voriconazole Inhalation Powder ((TFF VORI)) for the treatment and prevention of Invasive Pulmonary Aspergillosis (IPA). Patients with asthma and a portion of patients with cystic fibrosis and ch...

Initial data from Phase 1b showed Voriconazole Inhalation Powder is Well Tolerated in Asthma Patients Data Supports Progress to Phase 2 and Inclusion of Patients with Asthma AUSTIN, Texas, Nov. 08, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinic...

AUSTIN, Texas, Nov. 08, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that P...

AUSTIN, Texas, Nov. 05, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that i...

TFF Pharmaceuticals (TFFP +0.3%) has received approval from Health Canada to begin a Phase 1 trial of a dry powder formulation of niclosamide, an antiviral treatment with potential to address COVID-19 and other infectious diseases. The company anticipates the first patient will be dosed in th...

First Patient in Phase 1 Trial to be Dosed in November with Enrollment Completion Anticipated by Early Q1 2022 Preclinical Studies of Inhaled Dry Powder Formulation of Niclosamide Showed a Seven-Fold Reduction in Lung Viral Load in Hamsters When Administered 24 Hours After Inocu...

Results published in bioRxiv Show That Delivery of Dry Powder AUG-3387 Following Viral Inoculation Led to Dose-Dependent Reduction in Lung Viral Load in Hamsters Dry Powder Formulations Show Equivalent Binding as Original Antibody with No Loss of Biologic Activity Stud...

AUSTIN, Texas, Sept. 23, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced ...